StockData
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. (SPRY) stock

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$3.65+0.06 (+1.67%)

Close on Nov 17, 2026Market cap $362.98MP/E –Yield –

ARS Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ARS Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$216.27M. For fiscal 2025 it was -$179.45M. The highest annual figure on record is -$3.08M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$179.45M–
FY2024Dec 31, 2024-$3.08M–
FY2023Dec 31, 2023-$67.52M–
FY2022Dec 31, 2022-$35.52M–
FY2021Dec 31, 2021-$19.45M–
FY2020Dec 31, 2020-$32.92M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$61.47M–
Q1 FY2026Mar 31, 2026-$60.15M–
Q4 FY2025Dec 31, 2025-$41.47M-187.9%
Q3 FY2025Sep 30, 2025-$53.19M–
Q2 FY2025Jun 30, 2025-$47.61M–
Q1 FY2025Mar 31, 2025-$37.18M–
Q4 FY2024Dec 31, 2024$47.20M–
Q3 FY2024Sep 30, 2024-$21.75M–
Q2 FY2024Jun 30, 2024-$15.34M–
Q1 FY2024Mar 31, 2024-$13.19M–
Q4 FY2023Dec 31, 2023-$10.23M–
Q3 FY2023Sep 30, 2023-$17.98M–
Q2 FY2023Jun 30, 2023-$20.60M–
Q1 FY2023Mar 31, 2023-$18.71M–
Q4 FY2022Dec 31, 2022-$15.44M-133.1%
Q3 FY2022Sep 30, 2022-$6.63M–
Q2 FY2022Jun 30, 2022-$6.34M–
Q1 FY2022Mar 31, 2022-$7.10M–
Q4 FY2021Dec 31, 2021$46.62M–
Q3 FY2021Sep 30, 2021-$22.68M–
Q2 FY2021Jun 30, 2021-$24.51M–
Q1 FY2021Mar 31, 2021-$18.89M–
Q4 FY2020Dec 31, 2020-$13.10M–
Q3 FY2020Sep 30, 2020-$8.11M–
Q2 FY2020Jun 30, 2020-$6.46M–
Q1 FY2020Mar 31, 2020-$5.24M–

More ARS Pharmaceuticals figures

See a number that looks wrong?